MH
Therapeutic Areas
CAMP4 Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Undisclosed PRAM (SCN1A-targeting) | Dravet Syndrome | Preclinical |
| Undisclosed PRAM (CDKL5-targeting) | CDKL5 Deficiency Disorder | Preclinical |
| Undisclosed PRAM (OTC-targeting) | Ornithine Transcarbamylase (OTC) Deficiency | Preclinical |
Leadership Team at CAMP4 Therapeutics
JM
Joshua Mandel-Brehm, J.D.
President, Chief Executive Officer, and Board Member
VS
Vivian S. Lee, M.D., Ph.D.
Chief Medical Officer
GF
Gregory F. Covino, CPA
Chief Financial Officer
RA
Richard A. Young, Ph.D.
Scientific Co-Founder, Professor at MIT, Member of Whitehead Institute
DM
David M. Bartel, Ph.D.
Scientific Co-Founder, Professor at MIT, HHMI Investigator